|
1
|
Locksley RM, Killeen N and Lenardo MJ: The
TNF and TNF receptor superfamilies: integrating mammalian biology.
Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bodmer JL, Schneider P and Tschopp J: The
molecular architecture of the TNF superfamily. Trends Biochem Sci.
27:19–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chicheportiche Y, Bourdon PR, Xu H, et al:
TWEAK, a new secreted ligand in the tumor necrosis factor family
that weakly induces apoptosis. J Biol Chem. 272:32401–32410. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tran NL, McDonough WS, Savitch BA, Sawyer
TF, Winkles JA and Berens ME: The tumor necrosis factor-like weak
inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14
(Fn14) signaling system regulates glioma cell survival via NFkappaB
pathway activation and BCL-XL/BCL-W expression. J Biol Chem.
280:3483–3492. 2005. View Article : Google Scholar
|
|
5
|
Lynch CN, Wang YC, Lund JK, Chen YW, Leal
JA and Wiley SR: TWEAK induces angiogenesis and proliferation of
endothelial cells. J Biol Chem. 274:8455–8459. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harada N, Nakayama M, Nakano H, Fukuchi Y,
Yagita H and Okumura K: Pro-inflammatory effect of TWEAK/Fn14
interaction on human umbilical vein endothelial cells. Biochem
Biophys Res Commun. 299:488–493. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kawakita T, Shiraki K, Yamanaka Y, et al:
Functional expression of TWEAK in human hepatocellular carcinoma:
possible implication in cell proliferation and tumor angiogenesis.
Biochem Biophys Res Commun. 318:726–733. 2004. View Article : Google Scholar
|
|
8
|
Donohue PJ, Richards CM, Brown SA, et al:
TWEAK is an endothelial cell growth and chemotactic factor that
also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler
Thromb Vasc Biol. 23:594–600. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tran NL, McDonough WS, Donohue PJ, et al:
The human Fn14 receptor gene is up-regulated in migrating glioma
cells in vitro and overexpressed in advanced glial tumors. Am J
Pathol. 162:1313–1321. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perper SJ, Browning B, Burkly LC, et al:
TWEAK is a novel arthritogenic mediator. J Immunol. 177:2610–2620.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamill CA, Michaelson JS, Hahm K, Burkly
LC and Kessler A: Age-dependent effects of TWEAK/Fn14 receptor
activation on neural progenitor cells. J Neurosci Res.
85:3535–3544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marsters SA, Sheridan JP, Pitti RM, Brush
J, Goddard A and Ashkenazi A: Identification of a ligand for the
death-domain-containing receptor Apo3. Curr Biol. 8:525–528. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakayama M, Kayagaki N, Yamaguchi N,
Okumura K and Yagita H: Involvement of TWEAK in interferon
gamma-stimulated monocyte cytotoxicity. J Exp Med. 192:1373–1380.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meighan-Mantha RL, Hsu DK, Guo Y, et al:
The mitogeninducible Fn14 gene encodes a type I transmembrane
protein that modulates fibroblast adhesion and migration. J Biol
Chem. 274:33166–33176. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tran NL, McDonough WS, Savitch BA, et al:
Increased fibroblast growth factor-inducible 14 expression levels
promote glioma cell invasion via Rac1 and nuclear factor-kappaB and
correlate with poor patient outcome. Cancer Res. 66:9535–9542.
2006. View Article : Google Scholar
|
|
16
|
Winkles JA: The TWEAK-Fn14
cytokine-receptor axis: discovery, biology and therapeutic
targeting. Nat Rev Drug Discov. 7:411–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Watts GS, Tran NL, Berens ME, et al:
Identification of Fn14/TWEAK receptor as a potential therapeutic
target in esophageal adenocarcinoma. Int J Cancer. 121:2132–2139.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Winkles JA, Tran NL, Brown SA, Stains N,
Cunliffe HE and Berens ME: Role of TWEAK and Fn14 in tumor biology.
Front Biosci. 12:2761–2771. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Winkles JA, Tran NL and Berens ME: TWEAK
and Fn14: new molecular targets for cancer therapy? Cancer Lett.
235:11–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li H, Mittal A, Paul PK, et al: Tumor
necrosis factor-related weak inducer of apoptosis augments matrix
metalloproteinase 9 (MMP-9) production in skeletal muscle through
the activation of nuclear factor-kappaB-inducing kinase and p38
mitogen-activated protein kinase: a potential role of MMP-9 in
myopathy. J Biol Chem. 284:4439–4450. 2009.
|
|
21
|
Michaelson JS, Cho S, Browning B, et al:
Tweak induces mammary epithelial branching morphogenesis. Oncogene.
24:2613–2624. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim SH, Kang YJ, Kim WJ, et al: TWEAK can
induce pro-inflammatory cytokines and matrix metalloproteinase-9 in
macrophages. Circ J. 68:396–399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jakubowski A, Ambrose C, Parr M, et al:
TWEAK induces liver progenitor cell proliferation. J Clin Invest.
115:2330–2340. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Preter K, Vandesompele J, Heimann P, et
al: Human fetal neuroblast and neuroblastoma transcriptome analysis
confirms neuroblast origin and highlights neuroblastoma candidate
genes. Genome Biol. 7:R842006.
|
|
26
|
McArdle L, McDermott M, Purcell R, et al:
Oligonucleotide micro-array analysis of gene expression in
neuroblastoma displaying loss of chromosome 11q. Carcinogenesis.
25:1599–1609. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wilzen A, Nilsson S, Sjoberg RM, Kogner P,
Martinsson T and Abel F: The Phox2 pathway is differentially
expressed in neuroblastoma tumors, but no mutations were found in
the candidate tumor suppressor gene PHOX2A. Int J Oncol.
34:697–705. 2009.
|
|
28
|
Molenaar JJ, Ebus ME, Koster J, et al:
Cyclin D1 and CDK4 activity contribute to the undifferentiated
phenotype in neuroblastoma. Cancer Res. 68:2599–2609. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brodeur GM, Pritchard J, Berthold F, et
al: Revisions of the international criteria for neuroblastoma
diagnosis, staging, and response to treatment. J Clin Oncol.
11:1466–1477. 1993.PubMed/NCBI
|
|
30
|
Sontag E, Sontag JM and Garcia A: Protein
phosphatase 2A is a critical regulator of protein kinase C zeta
signaling targeted by SV40 small t to promote cell growth and
NF-kappaB activation. EMBO J. 16:5662–5671. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Johannessen M, Olsen PA, Sorensen R,
Johansen B, Seternes OM and Moens U: A role of the TATA box and the
general co-activator hTAF(II)130/135 in promoter-specific
trans-activation by simian virus 40 small t antigen. J Gen Virol.
84:1887–1897. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Malla N, Berg E, Uhlin-Hansen L and
Winberg JO: Interaction of pro-matrix
metalloproteinase-9/proteoglycan heteromer with gelatin and
collagen. J Biol Chem. 283:13652–13665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Winberg JO, Kolset SO, Berg E and
Uhlin-Hansen L: Macrophages secrete matrix metalloproteinase 9
covalently linked to the core protein of chondroitin sulphate
proteoglycans. J Mol Biol. 304:669–680. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dogra C, Changotra H, Mohan S and Kumar A:
Tumor necrosis factor-like weak inducer of apoptosis inhibits
skeletal myogenesis through sustained activation of nuclear
factor-kappaB and degradation of MyoD protein. J Biol Chem.
281:10327–10336. 2006. View Article : Google Scholar
|
|
35
|
Han S, Yoon K, Lee K, et al: TNF-related
weak inducer of apoptosis receptor, a TNF receptor superfamily
member, activates NF-kappa B through TNF receptor-associated
factors. Biochem Biophys Res Commun. 305:789–796. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saitoh T, Nakayama M, Nakano H, Yagita H,
Yamamoto N and Yamaoka S: TWEAK induces NF-kappaB2 p100 processing
and long lasting NF-kappaB activation. J Biol Chem.
278:36005–36012. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Johnsen JI, Pettersen I, Ponthan F,
Sveinbjornsson B, Flaegstad T and Kogner P: Synergistic induction
of apoptosis in neuroblastoma cells using a combination of
cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol.
25:1849–1857. 2004.PubMed/NCBI
|
|
38
|
Feng SL, Guo Y, Factor VM, et al: The Fn14
immediate-early response gene is induced during liver regeneration
and highly expressed in both human and murine hepatocellular
carcinomas. Am J Pathol. 156:1253–1261. 2000. View Article : Google Scholar
|
|
39
|
Wang S, Zhan M, Yin J, et al:
Transcriptional profiling suggests that Barrett’s metaplasia is an
early intermediate stage in esophageal adenocarcinogenesis.
Oncogene. 25:3346–3356. 2006.
|
|
40
|
De Ketelaere A, Vermeulen L, Vialard J, et
al: Involvement of GSK-3beta in TWEAK-mediated NF-kappaB
activation. FEBS Lett. 566:60–64. 2004.PubMed/NCBI
|
|
41
|
Yepes M, Brown SA, Moore EG, Smith EP,
Lawrence DA and Winkles JA: A soluble Fn14-Fc decoy receptor
reduces infarct volume in a murine model of cerebral ischemia. Am J
Pathol. 166:511–520. 2005.PubMed/NCBI
|
|
42
|
Tanabe K, Bonilla I, Winkles JA and
Strittmatter SM: Fibroblast growth factor-inducible-14 is induced
in axotomized neurons and promotes neurite outgrowth. J Neurosci.
23:9675–9686. 2003.PubMed/NCBI
|
|
43
|
Caren H, Kryh H, Nethander M, et al:
High-risk neuroblastoma tumors with 11q-deletion display a poor
prognostic, chromosome instability phenotype with later onset. Proc
Natl Acad Sci USA. 107:4323–4328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom
HN and Winkles JA: Soluble tumor necrosis factor-like weak inducer
of apoptosis overexpression in HEK293 cells promotes tumor growth
and angiogenesis in athymic nude mice. Cancer Res. 64:8968–8972.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao HX, Campbell SR, Burkly LC, et al:
TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and
proliferative effects in human kidney cells. Cytokine. 46:24–35.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chicheportiche Y, Chicheportiche R, Sizing
I, et al: Proinflammatory activity of TWEAK on human dermal
fibroblasts and synoviocytes: blocking and enhancing effects of
anti-TWEAK monoclonal antibodies. Arthritis Res. 4:126–133. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yokoo T and Kitamura M: Antioxidant PDTC
induces stromelysin expression in mesangial cells via a tyrosine
kinase-AP-1 pathway. Am J Physiol. 270:F806–F811. 1996.PubMed/NCBI
|
|
48
|
Huang S, Robinson JB, Deguzman A, Bucana
CD and Fidler IJ: Blockade of nuclear factor-kappaB signaling
inhibits angiogenesis and tumorigenicity of human ovarian cancer
cells by suppressing expression of vascular endothelial growth
factor and interleukin 8. Cancer Res. 60:5334–5339. 2000.
|
|
49
|
Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN
and Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB
p65 transcription factor in human vascular endothelial cells. J
Biol Chem. 272:601–608. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kwon OH, Park SJ, Kang TW, et al: Elevated
fibroblast growth factor-inducible 14 expression promotes gastric
cancer growth via nuclear factor-kappaB and is associated with poor
patient outcome. Cancer Lett. 314:73–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tonti GA, Mannello F, Cacci E and Biagioni
S: Neural stem cells at the crossroads: MMPs may tell the way. Int
J Dev Biol. 53:1–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hadler-Olsen E, Fadnes B, Sylte I,
Uhlin-Hansen L and Winberg JO: Regulation of matrix
metalloproteinase activity in health and disease. FEBS J.
278:28–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Farina AR, Tiberio A, Tacconelli A,
Cappabianca L, Gulino A and Mackay AR: Identification of
plasminogen in Matrigel and its activation by reconstitution of
this basement membrane extract. Biotechniques. 21:904–909.
1996.PubMed/NCBI
|
|
54
|
Ara T, Fukuzawa M, Kusafuka T, et al:
Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in
neuroblastoma: association with tumor progression and clinical
outcome. J Pediatr Surg. 33:1272–1278. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ribatti D, Surico G, Vacca A, et al:
Angiogenesis extent and expression of matrix metalloproteinase-2
and -9 correlate with progression in human neuroblastoma. Life Sci.
68:1161–1168. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Huang M, Narita S, Tsuchiya N, et al:
Overexpression of Fn14 promotes androgen-independent prostate
cancer progression through MMP-9 and correlates with poor treatment
outcome. Carcinogenesis. 32:1589–1596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Culp PA, Choi D, Zhang Y, et al:
Antibodies to TWEAK receptor inhibit human tumor growth through
dual mechanisms. Clin Cancer Res. 16:497–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Michaelson JS, Kelly R, Yang L, Zhang X,
Wortham K and JosepH IB: The anti-Fn14 antibody BIIB036 inhibits
tumor growth in xenografts and patient derived primary tumor models
and enhances efficacy of chemotherapeutic agents in multiple
xenograft models. Cancer Biol Ther. 13:812–821. 2012. View Article : Google Scholar : PubMed/NCBI
|
